After a failure in NASH, Gilead is playing the long game
Gilead Sciences’ recent history has been a story of running in place. The company built an enviable business treating deadly viruses, but its attempts to diversify into areas like oncology and inflammatory disease have never come close to comparable success. The company’s most recent major failure, a treatment for the liver disease NASH, is a clear example.
Into that dynamic walks Mark Genovese, a renowned rheumatologist who spent more than 20 years at Stanford and is now in charge of Gilead’s efforts to develop medicines for inflammatory diseases, including NASH. His task will be to find actual drugs amid a pipeline that has lagged behind competitors in recent years.
Genovese’s appointment is the latest in a string of personnel moves under Gilead CEO Daniel O’Day, who started the job just over a year ago. It also falls in line with O’Day’s strategic departure from his predecessors. Under Gilead’s old model of buying its way out of problems, the solution might have been to acquire a NASH biotech at a high premium. O’Day, by contrast, has played a longer game, and recruiting Genovese could prove to be what the company needs.
Into that dynamic walks Mark Genovese, a renowned rheumatologist who spent more than 20 years at Stanford and is now in charge of Gilead’s efforts to develop medicines for inflammatory diseases, including NASH. His task will be to find actual drugs amid a pipeline that has lagged behind competitors in recent years.
Genovese’s appointment is the latest in a string of personnel moves under Gilead CEO Daniel O’Day, who started the job just over a year ago. It also falls in line with O’Day’s strategic departure from his predecessors. Under Gilead’s old model of buying its way out of problems, the solution might have been to acquire a NASH biotech at a high premium. O’Day, by contrast, has played a longer game, and recruiting Genovese could prove to be what the company needs.
.png)
No hay comentarios:
Publicar un comentario